Oncolytic viruses – coming closer to breakthrough

  1. Klüglich, Matthias

Download
DOI-10.4126FRL01-006511317-PMQM125-p34-41-PM-Klueglich Kopie.pdf 396,80KB
WeightNameValue
1000 Titel
  • Oncolytic viruses – coming closer to breakthrough
1000 Titelzusatz
  • Oncotropic viruses to combat cancer: Despite clear proof of concept, no major successes reached so far
1000 Autor/in
  1. Klüglich, Matthias |
1000 Erscheinungsjahr 2025
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2025-05
1000 Erschienen in
1000 Quellenangabe
  • 27(1):34-41
1000 Embargo
  • 2026-05
1000 Lizenz
1000 Verlagsversion
  • https://www.dgpharmed.de/pm-qm-journal/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Introduction. Since the 19th century’s observation that infections can slow neoplastic growth and the discovery of viruses soon after, oncolytic virotherapy has continuously gained interest. Objective. The history and current state of Oncolytic Virus (OV) research, clinical development, and therapeutic availability is assessed and evaluated. Methods. Relevant publications summarizing OV research and development were reviewed. Numbers of trials and publications were taken from the publicly available data bases ClinicalTrials.Gov and PubMed. Results. Therapeutic virus research made significant progress with the advent of genetic engineering techniques. At the same time, elucidation of immunological mechanisms paved the way for targeted approaches. Today, four OVs are approved for cancer treatment, and a plethora of genetically modified OVs are in development. Oncotropism, tumour penetration, replication and multimodal triggering of anti-tumour immunogenicity form the basis of their efficacy. Oncolytic viruses are modified to target cancer cells, escape intratumoral control mechanisms, express specific binding sites, transcribe immunogenic cytokines and antibodies, and re-invigorate the tumour microenvironment (TME). Conclusion. An immense body of preclinical and phase-1 clinical data vastly confirms OV safety even though treatment benefit often is weak. Future research needs to focus on open questions of e.g. virus, patient and indication selection, modes of administration, and most promising cargos.
1000 Fächerklassifikation (DDC)
1000 DOI 10.4126/FRL01-006511317 |
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S2zDvGdsaWNoLCBNYXR0aGlhcw==
1000 Hinweis
  • Dieses Werk steht nach Ablauf des Embargos von 12 Monaten nach Veröffentlichung in diesem Journal unter einer CC BY 4.0 Lizenz frei zur Verfügung unter: https://doi.org/10.4126/FRL01-006511317
1000 Label
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
  1. Oncolytic viruses – coming closer to breakthrough
    Oncolytic viruses – coming closer to breakthrough
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6511317.rdf
1000 Erstellt am 2025-05-14T13:28:42.848+0200
1000 Erstellt von 338
1000 beschreibt frl:6511317
1000 Bearbeitet von 288
1000 Zuletzt bearbeitet 2025-05-26T09:54:57.062+0200
1000 Objekt bearb. Mon May 26 09:54:56 CEST 2025
1000 Vgl. frl:6511317
1000 Oai Id
  1. oai:frl.publisso.de:frl:6511317 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source